Discounted Cash Flow
Arcutis Biotherapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | — | — | — | — | — |
| 2018 | — | $-19.3m | $-14.1m | — | — |
| 2019 | — | $-42.0m (-118.1%) | $-43.1m (-206.2%) | — | — |
| 2020 | $0 | $-135.7m (-223.1%) | $-113.4m (-162.8%) | — | — |
| 2021 | $0 | $-206.4m (-52.1%) | $-175.6m (-54.9%) | — | $-4.18 |
| 2022 | $3.7m | $-311.5m (-50.9%) | $-258.0m (-46.9%) | -8449.8% | $-5.66 (-35.4%) |
| 2023 | $59.6m (1517.1%) | $-262.1m (15.8%) | $-247.5m (4.1%) | -439.8% (94.8%) | $-3.78 (33.2%) |
| 2024 | $196.5m (229.7%) | $-140.0m (46.6%) | $-112.3m (54.6%) | -71.3% (83.8%) | $-1.16 (69.3%) |
| 2025 | $376.1m (91.3%) | $-16.1m (88.5%) | $-6.3m (94.4%) | -4.3% (94.0%) | $-0.13 (88.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.